Bao Y. Study on the efficacy and safety of BCMA-targeted CAR-T in the treatment of relapsed/refractory multiple myeloma. Beijing: Tongfang Knowledge Network (Beijing) Technology Co., Ltd.; 2023. https://doi.org/10.27438/d.cnki.gyadu.2022.000460.

Bezeljak U. Cancer gene therapy goes viral: viral vector platforms come of age. Radiol Oncol. 2022;56(1):1–13. https://doi.org/10.2478/raon-2022-0002.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger DSB, Matthew JF, Olszanski AJ, Vincent KL, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGEA10+ advanced non-small cell lung cancer. J ImmunoTherap Cancer. 2022;10(1):e003581. https://doi.org/10.1136/jitc-2021-003581.

Brudno JN, Natrakul DA, Karrs J, Patel N, Maass-Moreno R, Ahlman MA, Mikkilineni L, Mann J, Stroncek DF, Highfill SL, Fromm GC, Patel R, Pittaluga S, Kochenderfer JN. Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. Blood Adv. 2024;8(3):802–14. https://doi.org/10.1182/bloodadvances.2023011470.

Article  CAS  PubMed  Google Scholar 

Chambers D, Rodgers M, Woolacott N. Not only randomized controlled trials, but also case series should be considered in systematic reviews of rapidly developing technologies. J Clin Epidemiol. 2009;62(12):1253-1260 e1254. https://doi.org/10.1016/j.jclinepi.2008.12.010.

Article  PubMed  Google Scholar 

Claudepierre MC, Hortelano J, Schaedler E, Kleinpeter P, Geist M, Remy-Ziller C, Brandely R, Tosch C, Laruelle L, Jawhari A, Menguy T, Marchand JB, Romby P, Schultz P, Hartmann G, Rooke R, Bonnefoy JY, Preville X, Rittner K. Yeast virus-derived stimulator of the innate immune system augments the efficacy of virus vector-based immunotherapy. J Virol. 2014;88(10):5242–55. https://doi.org/10.1128/Jvi.03819-13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Conroy M, Naidoo J. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun. 2022;13(1):392. https://doi.org/10.1038/s41467-022-27960-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curran T, Sun ZQ, Gerry B, Findlay VJ, Wallace K, Li ZH, Paulos C, Ford M, Rubinstein MP, Chung DJ, Camp ER. Differential immune signatures in the tumor microenvironment are associated with colon cancer racial disparities. Cancer Med. 2021;10(5):1805–14. https://doi.org/10.1002/cam4.3753.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–9. https://doi.org/10.1002/ajh.25418.

Article  CAS  PubMed  Google Scholar 

Ferrucci PF, Pala L, Conforti F, Cocorocchio E. Talimogene Laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma. Cancers. 2021;13(6):1383. https://doi.org/10.3390/cancers13061383.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020;38(5):415–22. https://doi.org/10.1200/JCO.19.01892. Epub 2019 Dec 9.

Article  CAS  PubMed  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. https://doi.org/10.1038/s41392-022-00947-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gu R, Liu F, Zou D, Xu Y, Lu Y, Liu B, Liu W, Chen X, Liu K, Guo Y, Gong X, Lv R, Chen X, Zhou C, Zhong M, Wang H, Wei H, Mi Y, Qiu L, Lv L, Wang M, Wang Y, Zhu X, Wang J. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J Hematol Oncol. 2020;13(1):122. https://doi.org/10.1186/s13045-020-00953-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gyawali B, Hey SP, Kesselheim AS. A comparison of response patterns for progression-free survival and overall survival following treatment for cancer with PD-1 inhibitors: a meta-analysis of correlation and differences in effect sizes. Jama Netw Open. 2018;1(2):e180416. https://doi.org/10.1001/jamanetworkopen.2018.0416.

Article  PubMed  PubMed Central  Google Scholar 

Jardim DL, Goodman A, Gagliato DD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–73. https://doi.org/10.1016/j.ccell.2020.10.001.

Article  CAS  PubMed  Google Scholar 

Jiang H, Li C, Yin P, Guo T, Liu L, Xia L, Wu Y, Zhou F, Ai L, Shi W, Lu X, Wang H, Tang L, Wei Q, Deng J, Jin R, Xiong W, Dong J, Mei H, Hu Y. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am J Hematol. 2019;94(10):1113–22. https://doi.org/10.1002/ajh.25582. Epub 2019 Aug 2.

Article  CAS  PubMed  Google Scholar 

Jin X, Zhang M, Sun R, Lyu H, Xiao X, Zhang X, Li F, Xie D, Xiong X, Wang J, Lu W, Zhang H, Zhao M. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J Hematol Oncol. 2022;15(1):88. https://doi.org/10.1186/s13045-022-01308-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson RL, Cummings M, Thangavelu A, Theophilou G, de Jong D, Orsi NM. Barriers to immunotherapy in ovarian cancer: metabolic, genomic, and immune perturbations in the tumour microenvironment. Cancers. 2021;13(24):6231. https://doi.org/10.3390/cancers13246231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kciuk M, Yahya EB, Mohamed MMI, Rashid S, Iqbal MO, Kontek R, Abdulsamad MA, Allaq AA. Recent advances in molecular mechanisms of cancer immunotherapy. Cancers. 2023;15(10):2721. https://doi.org/10.3390/cancers15102721.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kendler KS, Sundquist K, Ohlsson H, Palmér K, Maes H, Winkleby MA, Sundquist J. Genetic and familial environmental influences on the risk for drug abuse. Arch Gen Psychiatry. 2012;69(7):690–7. https://doi.org/10.1001/archgenpsychiatry.2011.2112.

Article  PubMed  PubMed Central  Google Scholar 

Kumar M, Thangavel C, Becker RC, Sadayappan S. Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity. Cancers (Basel). 2020;13(1). https://doi.org/10.3390/cancers13010086.

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22(1):40. https://doi.org/10.1186/s12943-023-01740-y.

Article  PubMed  PubMed Central  Google Scholar 

Lao YF, Shen DM, Zhang WL, He R, Jiang M. Immune checkpoint inhibitors in cancer therapy-how to overcome drug resistance? Cancers. 2022;14(15):3575. https://doi.org/10.3390/cancers14153575.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, Chapuis A, Shadman M, Till BG, Cassaday RD, Milano F, Kiem HP, Riddell SR, Turtle CJ, Maloney DG, Gauthier J. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023;7(22):6990–7005. https://doi.org/10.1182/bloodadvances.2023011399.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Cao W, Que Y, Wang Q, Xiao Y, Gu C, Wang D, Wang J, Jiang L, Xu H, Xu J, Zhou X, Hong Z, Wang N, Huang L, Zhang S, Chen L, Mao X, Xiao M, Zhang W, Meng L, Cao Y, Zhang T, Li J, Zhou J. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med. 2021;11(3):e346. https://doi.org/10.1002/ctm2.346.

Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286–94. https://doi.org/10.1038/s41591-023-02496-0. Epub 2023 Aug 17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Yu Y, Wang G, Liu JY, Liu RJ, Liu LJ, Yang XX, Li HY, Gao CD, Lu Y, Zhuang J. From tumor mutational burden to characteristic targets analysis: identifying the predictive biomarkers and natural product interventions in cancer management. Front Nutr. 2022;9:989989. https://doi.org/10.3389/fnut.2022.989989.

Article